6505--Supply, TheraSphere Y90 - Nuclear Med, Cleveland

Closed Special Notice Posted

Solicitation number
36C25025Q0054
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Notice details come from SAM.gov. Updated .

About this opportunity

The Department of Veterans Affairs (VA) has issued a Special Notice announcing its intent to sole source the procurement of TheraSphere Y-90 doses from Boston Scientific. TheraSphere is a therapeutic agent used to treat unresectable primary Hepatocellular Carcinoma, consisting of microscopic glass spheres attached to a radioactive isotope. The VA cites the authority of FAR 13.5 and 41 U.S.C. 1901 to sole source this requirement, stating that only Boston Scientific can satisfy the agency's needs.

The purpose of this Special Notice is to provide an opportunity for other contractors to identify their interest and capabilities in providing the TheraSphere Y-90 product. Interested parties have until October 15, 2024 at 9AM EST to submit their information, which the VA will use to determine if the requirement should be competed. However, the decision to open the procurement to competition is solely at the discretion of the government. No solicitation is currently available, and all inquiries must be submitted by email to the Contracting Officer.

Notice text

Page 1 of 1

36C25025Q0054

SPECIAL NOTICE

NOTICE OF INTENT TO SOLE SOURCE

TheraSphere Y-90 Nuclear Med

The Department of Veterans Affairs, The Louis Stokes Cleveland Department of Veteran Affairs Medical Center, 10701 East Boulevard, Cleveland, Ohio 44106 intends to solicit and negotiate with only one source under the authority of FAR 13.5 and 41 U.S.C. § 1901 as implemented by FAR 13.106-1(b)(2), Only one responsible source and no other supplies or services will satisfy agency requirements. The VA intends to solicit and negotiate with Boston Scientific, 300 Boston Scientific Way, Marlborough, MA 01752, for TheraSphere Y-90 Doses.

TheraSphere, Y-90 glass microsphere is a therapeutic agent used to treat unresectable primary Hepatocellular Carcinoma. It consists of microscopic glass spheres that are attached to a radioactive isotope (Y-90) and then injected into the patient. The spheres are trapped in the liver where they can treat liver cancer.

The Government believes that only one business can satisfy the agency requirements and intends to negotiate with only one source under the authority of FAR 13.5 and 41 U.S.C. § 1901 as implemented by FAR 13.106-1(b)(2), Only one responsible source and no other supplies or services will satisfy agency requirements. Other persons may identify their interest and capability to respond to this requirement by Tuesday, October 15, 2024 at 9AM EST. Such capabilities information will be used solely for the purpose of determining whether or not to conduct this procurement on a competitive basis. All information shall be furnished at no cost or obligation to the Government. A determination by the Government not to open the requirement to competition based upon responses to this notice is solely within the discretion of the Government. No solicitation is available at this time. All inquiries must be submitted by email to Robert Blasko at robert.blasko@va.gov Enter RFQ 36C25025Q0054 TheraSphere Y-90 Nuclear Med in the email subject line.

Files

File Type Posted
36C25025Q0054.docx DOCX document

Similar open opportunities

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors